MARKET

CRMD

CRMD

Cormedix
NASDAQ
8.69
+0.03
+0.35%
Opening 12:26 06/17 EDT
OPEN
8.66
PREV CLOSE
8.66
HIGH
8.81
LOW
8.66
VOLUME
455.82K
TURNOVER
--
52 WEEK HIGH
17.43
52 WEEK LOW
6.13
MARKET CAP
681.75M
P/E (TTM)
4.114
1D
5D
1M
3M
1Y
5Y
1D
These small-cap healthcare stocks pair revenue growth with attractive valuations
Seeking Alpha · 5h ago
Weekly Report: what happened at CRMD last week (0608-0612)?
Weekly Report · 2d ago
CorMedix Secures Federal Circuit Win In MINOCIN Patent Case
NASDAQ · 06/08 15:38
CorMedix says appeals court upholds MINOCIN patent win, blocks Nexus generic until expiry
PUBT · 06/08 15:03
Federal Circuit Upholds CorMedix MINOCIN Patent Protection
TipRanks · 06/08 13:26
CorMedix announces United States Court of Appeals affirms patent judgements
TipRanks · 06/08 13:00
Federal Circuit upholds CorMedix win in MINOCIN patent case against Nexus
PUBT · 06/08 12:46
CorMedix Therapeutics Announces U.S. Court Of Appeals Affirmed Patent Infringement Judgement Ruling Against Nexus Pharmaceuticals
Benzinga · 06/08 12:34
More
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

Webull offers CorMedix Inc stock information, including NASDAQ: CRMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRMD stock methods without spending real money on the virtual paper trading platform.